ClinicalTrials.gg
CompletedNCT02461771ASAP IIUpdated Oct 6, 2020Results posted

Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal Pegcetacoplan (APL-2) for Patients With Wet AMD

A Phase 1 interventional study of Pegcetacoplan in Neovascular Age-Related Macular Degeneration, sponsored by Apellis Pharmaceuticals, Inc.. Completed at 4 sites in 2 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2020-10-06.

Sponsored by Apellis Pharmaceuticals, Inc. (part of Biogen) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Jan 2015, registered Jun 2015).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
13
Allocation
Non-randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 645 studies in Macular Degeneration with a site in United States — 84 open to participants now, 128 under way, 24 of them phase 3. Macular Degeneration · United States.

Enrollment
427th of 491
13 · median 55
Started
2015
with 31 others
Phase 1
91 of 645
10 open now
Registered
320th of 645
by date

Among the 645 studies in Macular Degeneration with a site in United States, this one is the 427th largest by enrollment of the 491 interventional ones that give a count, is one of 32 that started in 2015, is one of 91 in phase 1, and was the 320th registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

84 of the 645 studies in Macular Degeneration with a site in United States are open now. Recruiting first, the newest first:

79 more — sign in →

All 84 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 645 studies in Macular Degeneration with a site in United States, or all of them as a file.
02

Study summary

The objective of this study is to provide initial safety, tolerability and pharmacokinetics information of intravitreal administration of pegcetacoplan in order to support further development into larger Phase II studies for treatment of patients with AMD.

03

Conditions studied

  • Neovascular Age-Related Macular Degeneration

Keywords

  • AMD
  • Wet AMD
  • Neovascular AMD
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or Female
  2. Age ≥ 50 years
  3. The presence of an active choroidal neovascular lesion secondary to AMD
  4. On treatment with anti-VEGF therapy (Lucentis®, Eylea® or Avastin®)
  5. Must have received at least 3 anti-VEGF treatments over the 26-week period prior to screening (Screening Visit)
  6. Evidence that the macular fluid has responded to anti-VEGF in the past based on OCT in the opinion of PI
  7. At screening, evidence of subretinal fluid and retinal cystic changes
  8. Must have received anti-VEGF treatment within 10 days prior to pegcetacoplan treatment (anti-VEGF can be administered on the same day of the screening visit after the screening procedures have been completed)
  9. OCTs of sufficient quality to allow for the assessment of the central macular fluid can be obtained
  10. Female subjects must be:

    • Women of non- (WONCBP), Or
    • Women of child-bearing potential (WOCBP) with a negative pregnancy test at screening and must agree to use protocol defined methods of for the duration of the study
  11. Males with female partners of child-bearing potential must agree to use protocol defined methods of contraception and agree to refrain from donating sperm for the duration of the study
  12. Willing and able to give

Exclusion criteria

Exclusion Criteria:

  1. Choroidal neovascularization associated with other ocular diseases such as pathologic myopia, ocular histoplasmosis or posterior uveitis, etc
  2. Decreased vision due to retinal disease not attributable to choroidal neovascularization, such as nonexudative forms of AMD, geographic atrophy, inherited retinal dystrophy, uveitis or epiretinal membrane, a vitelliform-like lesion of the outer retina (e.g., as in pattern dystrophies or basal laminar drusen), idiopathic parafoveal telangiectasis, or central serous retinopathy
  3. Additional ocular diseases that have irreversibly compromised or, during follow-up, could likely compromise the VA of the study eye including amblyopia, anterior ischemic optic neuropathy, diabetic macular edema, severe non proliferative diabetic retinopathy, or proliferative diabetic retinopathy
  4. Decreased vision due to significant media opacity such as corneal disease or cataract, or opacity precluding photography of the retina
  5. Cataract surgery within three months of enrollment
  6. Presence of any hemorrhage
  7. History of treatment for CNV:

    1. Previous PDT treatment within 30 days prior to enrollment in the study
    2. Previous extrafoveal or juxtafoveal thermal laser photocoagulation within 30 days prior to enrollment in the study
  8. Intraocular surgery (including lens replacement surgery) within 3 months prior to randomization
  9. Medical problems that make consistent follow-up over the treatment period unlikely (e.g. stroke, severe MI, end stage ), or in general a poor medical risk because of other systemic diseases or active uncontrolled infections
  10. to fluorescein
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    Pegcetacoplan Cohort 1

    4 mg of pegcetacoplan 100 μL IVT injection

    Drug: Pegcetacoplan

  • Experimental
    Pegcetacoplan Cohort 2

    10 mg of pegcetacoplan 100 μL IVT injection

    Drug: Pegcetacoplan

  • Experimental
    Pegcetacoplan Cohort 3

    20 mg of pegcetacoplan 100 μL IVT injection

    Drug: Pegcetacoplan

Interventions

  • On treatment day, subjects will be administered a single 100 μL IVT injection of pegcetacoplan at the dose corresponding to their treatment assignment.

    Also known as: APL-2

06

What researchers measure

Primary outcomes

  1. Number of Subjects Who Experienced Ocular and Systemic Adverse Events (AEs), Including by Severity

    Safety was assessed throughout the study. A TEAE was defined as any AE that started on/after the IVT injection of pegcetacoplan.

    Time frame: Day 1 to Day 113

  2. Number of Dose Limiting Toxicities (DLTs)

    The occurrence of any of the following AEs were considered DLTs: intraocular inflammation (vitritis or uveitis), endophthalmitis, sustained elevation of intraocular pressure ≥30 millimeters (mm) of mercury, and/or sustained loss of visual acuity ≥15 letters not attributable to the injection procedure or progression of disease.

    Time frame: Day 1 to Day 15

  3. Median Area Under the Serum Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC[0-t])

    The AUC(0-t) was measured using the linear trapezoidal method when concentrations were increasing and the logarithmic trapezoidal method when concentrations were decreasing. The median AUC(0-t) is presented for each cohort.

    Time frame: Predose (screening), postdose Day 3 to Day 113

  4. Median Dose Normalized AUC(0-t)

    The AUC(0-t) was measured using the linear trapezoidal method when concentrations were increasing and the logarithmic trapezoidal method when concentrations were decreasing. The dose normalized AUC(0-t) was calculated for each subject by dividing the parameter by the subject's respective dose in milligrams. The median dose normalized AUC(0-t) is presented for each cohort.

    Time frame: Predose (screening), postdose Day 3 to Day 113

  5. Maximum Observed Serum Concentration (Cmax)

    The median Cmax is presented for each cohort.

    Time frame: Predose (screening), postdose Day 3 to Day 113

  6. Median Dose Normalized Cmax

    The dose normalized Cmax was calculated for each subject by dividing the parameter by the subject's respective dose in milligrams. The median dose normalized Cmax is presented for each cohort.

    Time frame: Predose (screening), postdose Day 3 to Day 113

  7. Median Time to the Maximum Measured Serum Concentration (Tmax)

    The median Tmax is presented for each cohort. If the maximum value occurred at more than 1 time point, Tmax was defined as the first time point with this value.

    Time frame: Predose (screening), postdose Day 3 to Day 113

Secondary outcomes

  1. Median Change From Baseline in Visual Acuity for the Study Eye

    Best Corrected Visual Acuity (BCVA) letter score was determined using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. The score ranges from 0 to 100 letters, lower number indicating reduced visual acuity; a positive value of change from baseline indicates visual acuity gain and a negative value indicates visual acuity loss.

    Time frame: Day 1 to Day 113

  2. Median Change From Baseline in Central Retinal Thickness, Central Retinal Lesion Thickness and Central Subfield Thickness in the Study Eye

    Central retinal thickness, central retinal lesion thickness and central subfield thickness were determined using Spectral Domain Optical Coherence Tomography (SD-OCT).

    Time frame: Day 1 to Day 113

  3. Median Change From Baseline in Macular Cube Volume in the Study Eye

    Macular cube volume was determined using SD-OCT.

    Time frame: Day 1 to Day 113

07

Results

Posted Oct 6, 2020

Participant flow

Male and female subjects aged at least 50 years with the presence of an active choroidal neovascular lesion secondary to age-related macular degeneration were recruited to this Phase 1 open-label, single-dose escalation study at 4 study centers in the United States and Australia.

Participant flow — Overall Study
MilestoneCohort 1Cohort 2Cohort 3
Started337
Completed337
Not completed000

Outcome measures

PrimaryNumber of Subjects Who Experienced Ocular and Systemic Adverse Events (AEs), Including by Severity

Safety was assessed throughout the study. A TEAE was defined as any AE that started on/after the IVT injection of pegcetacoplan.

Time frame:
Day 1 to Day 113
Reported as:
Count of participants · Participants
Number of Subjects Who Experienced Ocular and Systemic Adverse Events (AEs), Including by Severity
ParticipantsCohort 1Cohort 2Cohort 3
All TEAEs224
Ocular TEAEs112
Treatment-related AEs002
Serious AEs000
TEAEs leading to discontinuation000
PrimaryNumber of Dose Limiting Toxicities (DLTs)

The occurrence of any of the following AEs were considered DLTs: intraocular inflammation (vitritis or uveitis), endophthalmitis, sustained elevation of intraocular pressure ≥30 millimeters (mm) of mercury, and/or sustained loss of visual acuity ≥15 letters not attributable to the injection procedure or progression of disease.

Time frame:
Day 1 to Day 15
Reported as:
Number · Number of DLTs
Number of Dose Limiting Toxicities (DLTs)
Number of DLTsCohort 1Cohort 2Cohort 3
Number of Dose Limiting Toxicities (DLTs)000
PrimaryMedian Area Under the Serum Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC[0-t])

The AUC(0-t) was measured using the linear trapezoidal method when concentrations were increasing and the logarithmic trapezoidal method when concentrations were decreasing. The median AUC(0-t) is presented for each cohort.

Time frame:
Predose (screening), postdose Day 3 to Day 113
Reported as:
Median · micrograms*day/milliliter (μg*day/mL)
Median Area Under the Serum Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC[0-t])
micrograms*day/milliliter (μg*day/mL)Cohort 1Cohort 2Cohort 3
Median Area Under the Serum Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC[0-t])11.89 (11.49 to 13.90)29.95 (24.27 to 53.59)69.53 (55.06 to 86.92)
PrimaryMedian Dose Normalized AUC(0-t)

The AUC(0-t) was measured using the linear trapezoidal method when concentrations were increasing and the logarithmic trapezoidal method when concentrations were decreasing. The dose normalized AUC(0-t) was calculated for each subject by dividing the parameter by the subject's respective dose in milligrams. The median dose normalized AUC(0-t) is presented for each cohort.

Time frame:
Predose (screening), postdose Day 3 to Day 113
Reported as:
Median · (μg*day/mL)/respective mg dose
Median Dose Normalized AUC(0-t)
(μg*day/mL)/respective mg doseCohort 1Cohort 2Cohort 3
Median Dose Normalized AUC(0-t)2.97 (2.87 to 3.47)3.00 (2.43 to 5.36)3.48 (2.75 to 4.35)
PrimaryMaximum Observed Serum Concentration (Cmax)

The median Cmax is presented for each cohort.

Time frame:
Predose (screening), postdose Day 3 to Day 113
Reported as:
Median · μg/mL
Maximum Observed Serum Concentration (Cmax)
μg/mLCohort 1Cohort 2Cohort 3
Maximum Observed Serum Concentration (Cmax)0.383 (0.317 to 0.387)0.764 (0.596 to 1.610)2.140 (1.440 to 3.970)
PrimaryMedian Dose Normalized Cmax

The dose normalized Cmax was calculated for each subject by dividing the parameter by the subject's respective dose in milligrams. The median dose normalized Cmax is presented for each cohort.

Time frame:
Predose (screening), postdose Day 3 to Day 113
Reported as:
Median · (μg/mL)/respective mg dose
Median Dose Normalized Cmax
(μg/mL)/respective mg doseCohort 1Cohort 2Cohort 3
Median Dose Normalized Cmax0.096 (0.079 to 0.097)0.076 (0.060 to 0.161)0.107 (0.072 to 0.199)
PrimaryMedian Time to the Maximum Measured Serum Concentration (Tmax)

The median Tmax is presented for each cohort. If the maximum value occurred at more than 1 time point, Tmax was defined as the first time point with this value.

Time frame:
Predose (screening), postdose Day 3 to Day 113
Reported as:
Median · day
Median Time to the Maximum Measured Serum Concentration (Tmax)
dayCohort 1Cohort 2Cohort 3
Median Time to the Maximum Measured Serum Concentration (Tmax)14.0 (8.9 to 14.9)7.9 (7.0 to 14.9)15.0 (6.9 to 16.0)
SecondaryMedian Change From Baseline in Visual Acuity for the Study Eye

Best Corrected Visual Acuity (BCVA) letter score was determined using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. The score ranges from 0 to 100 letters, lower number indicating reduced visual acuity; a positive value of change from baseline indicates visual acuity gain and a negative value indicates visual acuity loss.

Time frame:
Day 1 to Day 113
Reported as:
Median · letters read correctly
Median Change From Baseline in Visual Acuity for the Study Eye
letters read correctlyCohort 1Cohort 2Cohort 3
Median Change From Baseline in Visual Acuity for the Study Eye1 (0 to 4)3 (-9 to 11)-1 (-4 to 10)
SecondaryMedian Change From Baseline in Central Retinal Thickness, Central Retinal Lesion Thickness and Central Subfield Thickness in the Study Eye

Central retinal thickness, central retinal lesion thickness and central subfield thickness were determined using Spectral Domain Optical Coherence Tomography (SD-OCT).

Time frame:
Day 1 to Day 113
Reported as:
Median · micrometers
Median Change From Baseline in Central Retinal Thickness, Central Retinal Lesion Thickness and Central Subfield Thickness in the Study Eye
micrometersCohort 1Cohort 2Cohort 3
Retinal thickness-106 (-129 to 71.5)5.0 (-109 to 22.0)37.5 (-9.5 to 170.5)
Retinal lesion thickness-79.5 (-128 to 64.0)2.5 (-104 to 31.5)19.0 (-21.5 to 212.0)
Central Subfield Thickness-29.0 (-48.0 to 42.0)-12.0 (-80.0 to 20.0)65.0 (-11.0 to 138.0)
SecondaryMedian Change From Baseline in Macular Cube Volume in the Study Eye

Macular cube volume was determined using SD-OCT.

Time frame:
Day 1 to Day 113
Reported as:
Median · mm^3
Median Change From Baseline in Macular Cube Volume in the Study Eye
mm^3Cohort 1Cohort 2Cohort 3
Median Change From Baseline in Macular Cube Volume in the Study Eye-0.4 (-2.1 to 0.2)-0.1 (-0.3 to 0.2)0.3 (-0.3 to 0.7)

Adverse events

Collected over TEAEs were collected from Day 1 up to the final study visit at Day 113 (approximately 16 weeks).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 10/3 (0%)0/3 (0%)2/3 (66.7%)
Cohort 20/3 (0%)0/3 (0%)2/3 (66.7%)
Cohort 30/7 (0%)0/7 (0%)4/7 (57.1%)
Most frequent other events
Showing 10 of 13
Most frequent other events
EventCohort 1Cohort 2Cohort 3
Eye painEye disorders1/30/32/7
Retinal haemorrhageEye disorders0/31/30/7
HordeolumInfections and infestations0/31/30/7
Back painMusculoskeletal and connective tissue disorders0/31/30/7
Skin irritationSkin and subcutaneous tissue disorders0/31/30/7
HypertensionVascular disorders1/31/30/7
Foreign body sensation in eyesEye disorders0/30/31/7
Vision blurredEye disorders0/30/31/7
PyrexiaGeneral disorders0/30/31/7
Urinary tract infectionInfections and infestations0/30/31/7

Baseline characteristics

The safety set included all subjects who received any amount of study drug.

Age, Continuous
Age, Continuous(years)Cohort 1Cohort 2Cohort 3Total
Median70 (60 to 73)79 (74 to 81)72 (68 to 93)73 (60 to 93)
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1Cohort 2Cohort 3Total
Female1258
Male2125
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort 1Cohort 2Cohort 3Total
White33713
Hispanic or Latino0123
Non-Hispanic or Latino32510
08

Study locations

4 sites
  • United States, California
    Beverly Hills, California 90211, United States
  • United States, Florida
    Miami, Florida 33136, United States
  • United States, New Hampshire
    Portsmouth, New Hampshire 03801, United States
  • Australia, New South Wells
    Parramatta, New South Wales 2150, Australia
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2015 to primary completion in Mar 2016, 13 months.

Results were first posted in Oct 2020, 4 years 6 months after primary completion.

Of 60 industry-sponsored phase 1 interventional studies under Macular Degeneration, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 27. This study's 13 months is below that.

Counting every sponsor, half of 75 studies reached it within 18 months; a quarter within 10 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2015
First posted
Jun 3, 2015
StartActual
Jan 28, 2015
Primary completionActual
Mar 8, 2016
CompletionActual
Mar 8, 2016
Results first posted
Oct 6, 2020
Last update
Oct 6, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 6, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02461771
Responsible party
Sponsor
First posted
Jun 3, 2015
Start date
Jan 28, 2015
Primary completion
Mar 8, 2016
Completion
Mar 8, 2016
Results posted
Oct 6, 2020
Last update
Oct 6, 2020

Study contacts

Federico Grossi, MD PhD
study director · Apellis Pharmaceuticals, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegcetacoplan

Start the discussion